Gufic Biosciences Announces 42nd AGM on Sept 4, 2026, Declares 10% Dividend
Gufic Biosciences will hold its 42nd AGM on September 4, 2026, to approve the FY26 financial statements and a 10% final dividend (₹0.10/share). The register of members will close from August 29 to September 4, 2026. The company also plans to re-appoint Pankaj J. Gandhi as Whole Time Director for five years.
The AGM and dividend declaration are important for shareholders and governance, impacting investor relations and potential shareholder returns. The re-appointment of a key managerial person also has strategic implications for the company's leadership.
The announcement is a routine corporate event (AGM) and dividend declaration, which are standard procedures. While the dividend is positive, the overall announcement is informational and does not indicate a significant positive or negative shift in the company's performance or outlook.
Gufic Biosciences Limited has announced its 42nd Annual General Meeting (AGM) will be held on Friday, September 04, 2026, at 3:30 p.m. IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The meeting will address ordinary and special businesses as detailed in the Notice of 42nd AGM dated July 31, 2026.
Furthermore, the company has informed that its Register of Members and Share Transfer Books will remain closed from Saturday, August 29, 2026, to Friday, September 04, 2026, inclusive. This closure is for the purpose of the AGM and the payment of a final dividend for the financial year ended March 31, 2026, subject to shareholder approval.
The proposed final dividend is 10%, equivalent to ₹0.10 per equity share of face value ₹1 each, for the financial year 2025-26. The record date for this dividend payment and AGM purposes is Friday, August 28, 2026. The AGM agenda includes considering and adopting the audited standalone and consolidated financial statements for FY 2025-26, appointing a director, ratifying the remuneration of cost auditors, and re-appointing Mr. Pankaj J. Gandhi as a Whole Time Director for a further period of five years from September 07, 2026, to September 06, 2031. The proposed remuneration for Mr. Gandhi includes a salary not exceeding ₹1,00,00,000 per annum, along with other perquisites and allowances.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.